Tryptamine Therapeutics Limited (ASX: TYP) - Precision Psychedelic Therapy -Treating neuropsychiatric Disorders.
- Noel Ong
- Aug 29
- 6 min read
Announcement
Tryptamine Therapeutics Limited (ASX: TYP) is sharpening its position in the psychedelic medicine sector with continued progress across its precision psilocin program. Focused on treating eating disorders and chronic pain, the company’s lead formulation, TRP-8803, is designed to overcome the shortcomings of oral psilocybin by delivering precision dosing, rapid onset, and a treatment model built for commercial scalability.
Recent updates across clinical and corporate fronts highlight not only the scientific validation of Tryptamine’s approach but also the financial reinforcement needed to accelerate development.
Highlights from Recent Updates - All About Precision Psychedelic Therapy.
Clinical Pipeline Progress
Binge Eating Disorder (BED): Phase 2a results at the University of Florida showed over 80% reduction in binge episodes using TRP-8802 (oral psilocybin) (Figure 1).
Figure 1: TYP- Phase 2A Interim Analysis with University of Florida (TRP-8802) (source: TYP)
Transition to TRP-8803 (IV psilocin) is now underway, with a world-first Swinburne University trial in preparation.
Fibromyalgia: Patient dosing has been completed in collaboration with the University of Michigan. Data will be presented at the International Association for the Study of Pain Conference in the Netherlands.
TYP – PHASE 2A FM STUDY WITH UNIVERSITY OF MICHIGAN (TRP-8802)
FMS characterised by widespread musculoskeletal pain, profound fatigue, sleep disturbances, and numerous other symptoms
Symptoms of fibromyalgia often begin after physical or emotional trauma, such as an illness, surgery, infection, life event or injury
While fibromyalgia pain feels like it's coming from a specific area of your body, it's actually originating in your brain, specifically from the nervous system
Many drugs have a limited effect on Fibromyalgia Pain
Co-morbidities include depression and health-related anxiety, sleep disturbances and increased suicide risk.
Figure 2: How Fibromyalgia Affects the Body (source: TYP)
Irritable Bowel Syndrome (IBS): A Phase 2a trial with Massachusetts General Hospital (Harvard) has commenced, with the first patient dosed in July 2024.
First-in-Human IV Psilocin Study
Conducted in Adelaide, the initial cohort has been successfully dosed with TRP-8803.
The 140-minute IV infusion demonstrated:
Rapid onset of the psychedelic state (~15 minutes).
Precision control of blood levels (Figure 2).
Figure 3: TRP-8803 Delivers Consistent Therapeutic Blood Levels (source: TYP)
Shortened treatment duration (1–2 hours) improves clinical and commercial feasibility.
Intellectual Property
Patent protections extend across formulation, dosing methods, and therapeutic indications, including BED, fibromyalgia, and IBS.
This strengthens the company’s long-term competitive positioning as the program scales.
Strengthened Financial Position
On 12 August 2025, Tryptamine secured a $2.6m non-dilutive R&D loan facility with Rockford Equity Pty Ltd, secured against FY26 R&D expenditure.
The facility complements existing cash reserves of $3.03m (as at 30 June 2025) and a pending $800,000 R&D tax rebate, providing flexibility to fast-track TRP-8803 trials.
CEO Jason Carroll commented:
“This agreement provides the Company with financial flexibility at a pivotal time in development of lead asset, TRP-8803. The capital, if required, will be used towards fast tracking a number of key development milestones, including our trial into BED with Swinburne, as well as other opportunities which are very well advanced.”
Next Steps
Tryptamine is preparing to advance TRP-8803 into Phase 2b/3 clinical trials, marking the next stage of development for its precision psilocin program. The company’s progress will be driven by its ongoing collaborations with leading academic institutions, which provide both scientific validation and global credibility.
Upcoming clinical data readouts from the fibromyalgia and IBS studies will play a pivotal role in shaping the development pathway and reinforcing the therapeutic potential of IV-infused psilocin. At the same time, the Swinburne University trial for Binge Eating Disorder (BED) is moving toward dosing completion, positioning Tryptamine at the forefront of a world-first clinical initiative in this indication.
To support these milestones, the Company now has access to a non-dilutive $2.6m loan facility, which, together with its cash reserves and R&D rebates, provides the financial flexibility to accelerate progress without immediate reliance on equity dilution. This dual focus on scientific advancement and financial discipline underpins Tryptamine’s strategy as it builds toward the next stage of development.
Samso Concluding Comments
Tryptamine Therapeutics is steadily building a case for its precision psilocin platform, with each clinical milestone reinforcing the potential of TRP-8803 to redefine psychedelic-assisted therapy. By targeting conditions such as binge eating disorder, fibromyalgia, and IBS, the company is deliberately focusing on patient populations with few effective treatment options and high unmet needs.
The recent first-in-human IV psilocin study provides an important technical validation—showing controlled dosing, faster onset, and a shorter treatment window. These elements not only enhance the patient and clinician experience but also address the critical commercial challenge of scaling psychedelic medicine.
The $2.6m non-dilutive facility, alongside existing reserves, gives Tryptamine room to accelerate its trials without the immediate pressure of equity dilution. For a small-cap ASX biotech, this balance between capital management and clinical ambition is significant.
As the next phase unfolds, investors should focus on the upcoming clinical data readouts, the Swinburne BED trial, and the broader regulatory environment for psychedelic therapies. Tryptamine’s progress illustrates the convergence of science, strategy, and market timing— elements that can transform a research-driven platform into a commercially scalable solution.
The Samso Way – Seek the Research
At Samso, we believe that understanding a company goes beyond the headlines. True insight comes from diving into the details, connecting clinical milestones, financial strategies, and market context. By seeking the research, investors gain clarity and perspective, allowing them to recognise real value when it emerges.
Our mission is simple: cut through the noise and spotlight what matters—genuine stories, grounded insights, and real opportunity.
Our content is well-researched and is only created if the team sees merit in discussing the company or concept. Investors can explore our three core platforms:
There may be numerous paths to success in investing, but the common thread among successful individuals is that they remain committed to making informed decisions. Equip yourself with the right knowledge and tools, and you will be well on your way to achieving your financial goals.
Most importantly, investors need to be absolutely diligent in understanding their own risk-reward tolerance and capabilities. Never bite off more than you can chew. As they say, Rome wasn’t built in a day, and the Great Wall stood because it took centuries to complete.
The Samso Philosophy:
Stay curious. Stay sharp. And remember—digging deeper always uncovers the real value.
In Life, there is no such thing as a Free Lunch.
Happy Investing, and the only four-letter word you need to know is DYOR.
To support our independent nature of our work, please head over to our Support Page and give us a helping hand in any of the ways listed. This is a new initiate for the Samso Platform, and it was always the concept of Samso when we started this journey in 2018.
Disclaimer
The information or opinions provided herein do not constitute investment advice, an offer or solicitation to subscribe for, purchase or sell the investment product(s) mentioned herein. It does not take into consideration, nor have any regard to your specific investment objectives, financial situation, risk profile, tax position or particular, or unique needs and constraints.
Share to Grow: Your Bonus
Samso has just released an eBook: How to Add Value to your Share Portfolio
A lesson on geological models sought by mining companies that gives insight and an understanding of which portfolios are better - and potentially more lucrative – investments. Click here to download this eBook.
If you find this article informative and useful, please help me share the information. I try and write about topics that are interesting and have the potential to be of investment value. It is not easy to find stories that fit those parameters. If you or your organisation see the benefit of what Samso is trying to achieve and has a need to share your journey, please contact me at noel.ong@samso.com.au.
Samso is a trusted platform that equips dedicated investors with up-to-date industry knowledge and insights from top CEOs and thought leaders. By staying informed on business advancements and market trends, investors can enhance their financial decisions through a combination of expert guidance and their own research.
Comments